Skip to main content
DongKookPharmaceuticalCo.,Ltd. logo

DongKookPharmaceuticalCo.,Ltd. — Investor Relations & Filings

Ticker · 086450 ISIN · KR7086450004 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2020-03-30 Audit Report / Informat…
Country KR South Korea
Listing KO 086450

About DongKookPharmaceuticalCo.,Ltd.

https://www.dkpharm.co.kr/en/

DongKook Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of medical products. Established in 1968, the company focuses on improving human health and quality of life. Its product portfolio includes prescription and non-prescription drugs, with key therapeutic areas in anesthetics, contrast media, anti-cancer agents, antibiotics, and oral healthcare treatments. The company operates its own Active Pharmaceutical Ingredient (API) synthesis facilities and invests in research and development to create innovative therapeutic solutions. It provides both finished products and raw materials to domestic and international markets.

Recent filings

Filing Released Lang Actions
사업보고서 (2019.12)
Audit Report / Information Classification · 99% confidence The document is a comprehensive financial report for Dongkook Pharmaceutical Co., Ltd., covering the fiscal year ending December 31, 2019. It includes the independent auditor's report, balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes to the financial statements. This structure is characteristic of an annual financial report. Although it is titled 'Audit Report' (감사보고서), in the context of corporate filings, this document serves as the primary annual financial disclosure for the company, which aligns with the 10-K category. FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and the election of directors and auditors. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the official outcomes of shareholder votes at an AGM.
2020-03-20 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation for executives falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the exchange.
2020-03-20 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director, including their name, term, and professional background. This falls under the category of board management and changes in corporate governance structure, which is classified as MANG (Board/Management Information).
2020-03-20 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Dongkook Pharmaceutical. It includes details about the meeting agenda, board activities, financial statements, and a correction notice (정정신고) regarding stock option grants. This type of document is a standard proxy statement/notice for an Annual General Meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2020-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from Dongkook Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and details regarding the audit process. While it contains financial data, it is a specific regulatory disclosure of the audit report results rather than the full 10-K annual report itself. Therefore, it is classified as an Audit Report/Information document. FY 2019
2020-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.